Scientific Journal of Immunology & Immunotherapy

Journal Information
Published by: SciRes Literature LLC (10.37871)
Total articles ≅ 2
Filter:

Articles in this journal

Yvette Redpath, Rajesh Thanasingh, Caroline Ponmani
Scientific Journal of Immunology & Immunotherapy, Volume 5, pp 001-004; https://doi.org/10.37871/sjii.id25

Abstract:
Diagnosing appendicitis in infants is challenging due to varied and heterogenous presentations. Whilst the condition is uncommon, the consequences of missing this in a busy Emergency Department (ED) can be catastrophic. We report an 8-month-old infant who presented to ED with a brief history of reduced feeding, lethargy and vomiting with normal observations. Excessive crying was noted when the child was supine, he was consolable when placed prone. Due to these paroxysms of crying which varied with position, investigations were commenced. He had a good clinical outcome. A high degree of suspicion is needed in preverbal children. Clinical examination, observation of the behaviour of the child and parental concern remain key to diagnosis. Through this paper we aim to explore the clinical conundrum of making the diagnosis in this age group and the modalities which help in decision making.
Blanco R, Rancés Blanco, Ramal M, Dominguez E, Chao L, Pérez D, Casavilca S, Sánchez B, Ledon N, Cedeño M
Scientific Journal of Immunology & Immunotherapy, Volume 4, pp 027-034; https://doi.org/10.37871/sjii.id24

Abstract:
Several biosimilars for Herceptin® (trastuzumab) and other innovator monoclonal antibodies (mAbs) against HER2 molecule have been developed and approved in the last years. Here, it is reported the binding properties of a novel anti-HER2 mAb (called 5G4) as well as the capacity of this mAb to inhibit cell proliferation and to induce Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). mAb 5G4 was compared with Herceptin® in a panel of human normal tissues, breast tumors and cell lines using immunohistochemistry, immunocytochemistry, western blot, flow cytometry and colorimetric methods. mAb 5G4 showed weak to moderate staining in breast ductal cells (1/2), gastric glandular cells (1/3) and renal tubes (2/3). Additionally, an intense reactivity was evident with mAb 5G4 in HER2-positive breast adenocarcinomas. The tissue staining was slightly more intense with Herceptin® (trastuzumab) that was used as control. Flow cytometry analysis revealed that mAb 5G4 is able to react with HER2 overexpressing cells (SK-BR-3 and SKOV3) comparable to Herceptin®. The relative binding and the anti-proliferative activity ranges of mAb 5G4 using Herceptin® as reference were between 91-115% and between 91-106%, respectively, which are considered comparable. Moreover, preliminary results suggest that the capacity of mAb 5G4 to induce ADCC in SK-BR-3 cells is non-inferior to Herceptin®. Our data permit to consider that mAb 5G4 has similar binding properties to HER2 antigen and biological activity compared with Herceptin®. However, further determinations such as affinity and FcgRIIIa binding activity of mAb 5G4 could be useful to confirm these results.
Back to Top Top